Patents by Inventor Lynn Morris

Lynn Morris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region
    Publication number: 20200199204
    Abstract: The present invention relates anti-HIV therapies and prophylaxis. Specifically, the invention relates to broadly neutralizing antibodies against HIV-1, nucleic acids encoding these antibodies, vectors comprising the nucleic acids and cells and pharmaceutical compositions Comprising said vectors and/or antibodies. The present invention also relates to use of the antibodies and/or vectors for the treatment and/or prevention of HIV-1 infection in a subject. Furthermore, the invention also relates to a kit containing the antibodies of the invention.
    Type: Application
    Filed: December 18, 2019
    Publication date: June 25, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Trustees of Columbia University in the City of New York, Centre for the AIDS Programme of Research in South Africa, National Health Laboratory Service
    Inventors: Chaim Aryeh Schramm, Jason Gorman, John Mascola, Lawrence Stewart Shapiro, Lynn Morris, Nicole Amy Doria-Rose, Penelope Linda Moore, Peter Dak-Pin Kwong, Salim Safurdeen Abdool Karim
  • Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region
    Patent number: 10519222
    Abstract: The present invention relates anti-HIV therapies and prophylaxis. Specifically, the invention relates to broadly neutralizing antibodies against HIV-1, nucleic acids encoding these antibodies, vectors comprising the nucleic acids and cells and pharmaceutical compositions Comprising said vectors and/or antibodies. The present invention also relates to use of the antibodies and/or vectors for the treatment and/or prevention of HIV-1 infection in a subject. Furthermore, the invention also relates to a kit containing the antibodies of the invention.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: December 31, 2019
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA, UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG, NATIONAL HEALTH LABORATORY SERVICE
    Inventors: Chaim Aryeh Schramm, Jason Gorman, John Mascola, Lawrence Stewart Shapiro, Lynn Morris, Nicole Amy Doria-Rose, Penelope Linda Moore, Peter Dak Pin Kwong, Salim Safurdeen Abdool Karim
  • Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region
    Publication number: 20160362479
    Abstract: The present invention relates anti-HIV therapies and prophylaxis. Specifically, the invention relates to broadly neutralizing antibodies against HIV-1, nucleic acids encoding these antibodies, vectors comprising the nucleic acids and cells and pharmaceutical compositions Comprising said vectors and/or antibodies. The present invention also relates to use of the antibodies and/or vectors for the treatment and/or prevention of HIV-1 infection in a subject. Furthermore, the invention also relates to a kit containing the antibodies of the invention.
    Type: Application
    Filed: February 27, 2015
    Publication date: December 15, 2016
    Applicants: The United states of America, as represented by the Secretary, Department of Health and Human Serv, The Trustees of Columbia University in the City of New York, Centre for the AIDS Programme of Research in South Africa, University of the Witwatersrand, Johannesburg, National Health Laboratory Service
    Inventors: Chaim Aryeh Schramm, Jason Gorman, John Mascola, Lawrence Stewart Shapiro, Lynn Morris, Nicole Amy Doria-Rose, Penelope Linda Moore, Peter Dak Pin Kwong, Salim Safurdeen Abdool Karim
  • HUMAN MONOCLONAL ANTIBODIES
    Publication number: 20160244510
    Abstract: The present invention relates, in general, to HIV-1-reactive antibodies and, in at least certain specific embodiments, to broadly neutralizing antibodies (bnAbs) (and fragments and derivatives thereof) and to compositions comprising same. The invention further relates to methods of using such bnAbs (and fragments and derivatives thereof) and compositions in immunotherapy regimens (e.g., passive immunotherapy regimens). The antibodies (and fragments and derivatives thereof) disclosed herein can also be used in methods of identifying candidate immunogens for use in inducing an immune response against HIV-1 in a mammal (e.g., a human). The invention also relates to such methods and to immunogens so identified.
    Type: Application
    Filed: September 26, 2014
    Publication date: August 25, 2016
    Inventors: M Anthony Moody, Hua-Xin Liao, Barton F Haynes, Lynn Morris
  • HIV-1 ANTIBODIES
    Publication number: 20120269821
    Abstract: The present invention relates, in general, to HIV-1 antibodies and, in particular, to broadly neutralizing HIV-1 antibodies that target the gp41 membrane-proximal external region (MPER).
    Type: Application
    Filed: December 8, 2011
    Publication date: October 25, 2012
    Inventors: Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody, Lynn Morris, Salim S. Abdool Karim
  • Nucleic acids encoding modified South African HIV-1 subtype C gag proteins
    Patent number: 7910716
    Abstract: Embodiments of the invention provide processes for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. A process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: March 22, 2011
    Assignees: Medical Research Council, University of Cape Town Observatory, University of North Carolina at Chapel Hill, Alphavax, Incorporated
    Inventors: Robert Edward Johnston, Salim Abdol Karim, Lynn Morris, Ronald Swanstrom, Carolyn Williamson
  • Process for the Selection of HIV-1 Subtype C Isolates, Selected HIV-1 Subtype Isolates, Their Genes and Modifications and Derivatives Thereof
    Publication number: 20090270488
    Abstract: Embodiments of the invention provide processes for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. A process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.
    Type: Application
    Filed: January 21, 2009
    Publication date: October 29, 2009
    Inventors: Robert Edward Johnston, Salim Abdol Karim, Lynn Morris, Ronald Swanstrom, Carolyn Williamson
  • process for the selection of HIV-1 subtype C isolates, selected HIV-1 subtype isolates, their genes and modifications and derivatives thereof
    Publication number: 20070172930
    Abstract: The invention provides a process for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. The process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.
    Type: Application
    Filed: March 15, 2007
    Publication date: July 26, 2007
    Inventors: Robert Johnston, Salim Karim, Lynn Morris, Roland Swanstrom, Carolyn Williamson
  • Process for the selection of hiv-1 subtype c Isolates, selected hiv-1 subtype c isolates, their genes and modifications and derivatives thereof
    Publication number: 20040116660
    Abstract: The invention provides a process for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. The process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.
    Type: Application
    Filed: September 12, 2003
    Publication date: June 17, 2004
    Inventors: Robert Edward Johnston, Salim Abdool Karim, Lynn Morris, Ronald Ivar Swanstrom, Carolynn Williamson